IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤内科
学科主题临床医学
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
Dong, Ningning; Yu, Jing; Wang, Chaoying; Zheng, Xiaohui; Wang, Zheng; Di, Lijun; Song, Guohong; Zhu, Budong; Che, Li; Jia, Jun; Jiang, Hanfang; Zhou, Xinna; Wang, Xiaoli; Ren, Jun
关键词Breast cancer Chemotherapy Cytochrome P450 Polymorphism
刊名JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2012-07-01
DOI10.1007/s00432-012-1183-5
138期:7页:1197-1203
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者Chinese National Science and Technology Major Project, Mega-Project for New Drugs Development ; Beijing Municipal Government Health Bureau ; Chinese National Science and Technology Major Project, Mega-Project for New Drugs Development ; Beijing Municipal Government Health Bureau
研究领域[WOS]Oncology
关键词[WOS]ANTHRACYCLINE-PRETREATED PATIENTS ; GENETIC POLYMORPHISMS ; CYTOCHROME-P450 1A1 ; PROSTATE-CANCER ; CYP1A1 GENE ; PHASE-III ; THERAPY ; RISK ; TAMOXIFEN ; SURVIVAL
英文摘要

Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC.

79 SNPs in CYP450, whose minor allele frequency were a parts per thousand yen10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson′s chi(2) test or Fisher′s exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes.

There is no significant association between polymorphisms and both objective response and OS. Only one SNP, CYP1A1 rs1048943 A > G (Ile462Val), was significantly associated with PFS (P = 0.0003). Multivariate analysis confirmed its prognostic significance for PFS (P = 0.004).

CYP1A1 rs1048943 A > G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients. However, confirmatory study is needed to validate this finding.

语种英语
所属项目编号2011ZX09302-001-02 ; 2009-2-16
资助者Chinese National Science and Technology Major Project, Mega-Project for New Drugs Development ; Beijing Municipal Government Health Bureau ; Chinese National Science and Technology Major Project, Mega-Project for New Drugs Development ; Beijing Municipal Government Health Bureau
WOS记录号WOS:000305196200012
引用统计
被引频次:10[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60114
专题北京大学临床肿瘤学院_肿瘤内科
作者单位Peking Univ Canc Hosp & Inst, Dept Med Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Dong, Ningning,Yu, Jing,Wang, Chaoying,et al. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,2012,138(7):1197-1203.
APA Dong, Ningning.,Yu, Jing.,Wang, Chaoying.,Zheng, Xiaohui.,Wang, Zheng.,...&Ren, Jun.(2012).Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,138(7),1197-1203.
MLA Dong, Ningning,et al."Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine".JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 138.7(2012):1197-1203.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Dong, Ningning]的文章
[Yu, Jing]的文章
[Wang, Chaoying]的文章
百度学术
百度学术中相似的文章
[Dong, Ningning]的文章
[Yu, Jing]的文章
[Wang, Chaoying]的文章
必应学术
必应学术中相似的文章
[Dong, Ningning]的文章
[Yu, Jing]的文章
[Wang, Chaoying]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。